Detailed Data Sharing Plans for Medical Research are Soon Due



Image Credit: Nat’l Institute of Health


New Data-Sharing Requirements from the NIH are a Big Step Toward More Open Science – and Potentially Higher-Quality Research

 

Starting on Jan. 25, 2023, many of the 2,500 institutions and 300,000 researchers that the U.S. National Institutes of Health supports will need to provide a formal, detailed plan for
publicly sharing the data generated by their research
. For many in the scientific community, this new NIH Data Management and Sharing Policy sounds like a no-brainer.

The incredibly quick development of rapid tests and vaccines for COVID-19 demonstrate the success that can follow the open sharing of data within the research community. The importance and impact of that data even drove a White House Executive Order mandating that “the heads of all executive departments and agencies” share “COVID-19-related data” publicly last year.

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Stephen Jacobs, Professor of Interactive Games and Media, Rochester Institute of Technology.

 

I am the Director of the Rochester Institute of Technology’s Open Programs Office. At Open@RIT, my colleagues and I work with faculty and researchers to help them openly share their research and data in a manner that provides others the rights to access, reuse and redistribute that work with as few barriers or restrictions as possible. In the sciences, these practices are often referred to as open data and open science.

The journal Nature has called the impact of the NIH’s new data management policy “seismic,” saying that it could potentially create a “global standard” for data sharing. This type of data sharing is likely to produce many benefits to science, but there also are some concerns over how researchers will meet the new requirements.

 


The National Institutes of Health has had data-sharing guidelines in place for years, but the new rules are by far the most comprehensive. NIH

 

What to Share and How to Share It

The NIH’s new policy around data sharing replaces a mandate from 2003. Even so, for some scientists, the new policy will be a big change. Dr. Francis S. Collins, then Director of the NIH, said in the 2020 statement announcing the coming policy changes that the goal is to “shift the culture of research” so that data sharing is the norm, rather than the exception.

Specifically, the policy requires two things. First, that researchers share all the scientific data that other teams would need in order to “validate and replicate” the original research findings. And second, that researchers include a two-page data management plan as part of their application for any NIH funding.

So what exactly is a data management plan? Take an imaginary study on heat waves and heatstroke, for example. All good researchers would collect measurements of temperature, humidity, time of year, weather maps, the health attributes of the participants and a lot of other data.

Starting next year, research teams will need to have determined what reliable data they will use, how the data will be stored, when others would be able to get access to it, whether or not special software would be needed to read the data, where to find that software and many other details – all before the research even begins so that these things can be included in the proposal’s data management plan.

Additionally, researchers applying for NIH funding will need to ensure that their data is available and stored in a way that persists long after the initial project is over.

The NIH has stated that it will support – with additional funding – the costs related to the collection, sharing and storing of data.

 

Sharing Data Promotes Open Science

The NIH’s case for the new policy is that it will be “good for science” because it maximizes availability of data for other researchers, addresses problems of reproducibility, will lead to better protection and use of data and increase transparency to ensure public trust and accountability.

The first big change in the new policy – to specifically share the data needed to validate and replicate – seems aimed at the proliferation of research that can’t be reproduced. Arguably, by ensuring that all of the relevant data from a given experiment is available, the scientific world would be better able to evaluate and validate through replication the quality of research much more easily.

I strongly believe that requiring data-sharing and management plans addresses a big challenge of open science: being able to quickly find the right data, as well as access, and apply it. The NIH says, and I agree, that the requirement for data management plans will help make the use of open data faster and more efficient. From the Human Genome Project in the 1990s to the recent, rapid development of tests and vaccines for COVID-19, the benefits of greater openness in science have been borne out.

 

Will the New Requirements be a Burden?

At its core, the goal of the new policy is to make science more open and to fight bad science. But as beneficial as the new policy is likely to be, it’s not without costs and shortfalls.

First, replicating a study – even one where the data is already available – still consumes expensive human, computing and material resources. The system of science doesn’t reward the researchers who reproduce an experiment’s results as highly as the ones who originate it. I believe the new policy will improve some aspects of replication, but will only address a few links in the overall chain.

Second are concerns about the increased workload and financial challenges involved in meeting the requirements. Many scientists aren’t used to preparing a detailed plan of what they will collect and how they will share it as a part of asking for funding. This means they may need training for themselves or the support of trained staff to do so.

Part of a Global Trend Toward Open Science

The NIH isn’t the only federal agency pursuing more open data and science. In 2013, the Obama administration mandated that all agencies with a budget of $100 million or more must provide open access to their publications and data. The National Science Foundation published their first open data policy two years earlier. Many European Union members are crafting national policies on open science – most notably France, which has already published its second.

The cultural shift in science that NIH Director Collins mentioned in 2020 has been happening – but for many, like me, who support these efforts, the progress has been painfully slow. I hope that the new NIH open data policy will help this movement gain momentum.

 

Suggested Reading



Stem Cell-Derived Retinal Pigment Epithelium Cells – Vision for the Future



House Approval Expected for Marijuana Opportunity Reinvestment and Expungement Act (MORE Act)





A Global Reimagined Health Ecosystem



Ultra-Rapid DNA Sequencing Identifies Rare Diseases in Hours

 

Main Image

Scientists discover how eye neurons in the eye may use math to distinguish moving objects.

 

Stay up to date. Follow us:

 

This SPAC Took a Different Track Which May Open Doors for Others



Image Credit: Michael McKibben


SPACs and Potential Sellers are Successfully Thinking Outside the Box

 

A new Special Purpose Acquisition Company arrangement may open the door to more successful SPAC mergers. The deal, once completed, involves a pharmaceutical company spinning off a division, which will then be acquired by the SPAC. There are several positive aspects for the shareholders of the original company, including tax breaks, as the SPAC, which went
public
in August of 2021, successfully merges with an attractive target.

The Deal

Ligand Pharmaceuticals (LGND) announced Wednesday (March 23) the spinoff of its antibody discovery technology division, OmniAb. It also announced the business would immediately merge with the Avista Public Acquisition Corp. II (AHPA). The deal values OmniAb at about $1.1 billion and would provide up to $266 million in cash to the new company. The stock of both companies responded to the announcement positively and outperformed the related market indices. Avista/AHPA will provide at least $115 million of gross cash to the combined company through a $15 million PIPE investment and a $100 million facility to backstop potential redemptions. Ligand’s $15 million contribution to OmniAb will be made irrespective of the number of redemptions or the Avista contributions.

Ligand intends to distribute 100% of the equity in OmniAb to Ligand shareholders immediately prior to the business combination with APAC. The transaction will be effected through a “Reverse Morris Trust” transaction pursuant to which OmniAb will be spun-off to Ligand’s shareholders and simultaneously merged as a subsidiary of AHPA. The transaction is expected to be tax-free to Ligand and its shareholders for U.S. federal income tax purposes, except for cash received in lieu of fractional shares. Once the transaction has closed, Ligand shareholders are expected to own approximately 75% to 84% of the combined company, depending on redemptions. It will then be Nasdaq listed under the ticker symbol “OABI”.

 

What
is Reverse Morris Trust?

The Reverse Morris Trust is a form of tax-avoidance employed by companies. This tactic enables the company to sell off unwanted assets without incurring tax obligations on gains arising from the sale of these assets.

The Reverse Morris Trust technique works in the following manner: a parent company spins off a subsidiary to which it transfers the unwanted assets; a new, unrelated company is formed by a merger of the subsidiary with a third party company; the new company issues at least 50.1% of its voting stock (and thus, control) to the shareholders of the original parent company.

                       Source: Corporate
Finance Institute

 

Why it May Open More SPAC M&A Doors

SPAC IPOs ran at a historically high pace at the end of 2020, and the beginning of 2021. The pace seemed to have run ahead of the availability of well-suited merger targets – there just have not been enough viable companies with the desire to be acquired. Most SPACs force a merger deal to be in place within 24 months or the SPAC fails, and the remaining funds are returned to the investors. The largest risk to the investors is usually seen as opportunity cost of their cash. The risk to the SPAC’s management is that finding a suitable deal is challenging.

The nature of this pharmaceutical company deal, spin-off, Reverse Morris Trust, then merger, may inspire both potential targets and potential acquirers to think differently and shop with a newly expanded list.

 

Tax Benefits

The spin-off and acquisition is being done through a Reverse Morris Trust. Ligand benefits by saving taxes compared to selling Instead of selling an asset outright and generating a gain on sale, the asset is spun off, and then merged with a company interested in owning the asset. The shareholders of the spinoff, for tax reasons, have to end up with the majority of the merger partner’s stock. This means the spun-off asset is, essentially, the larger party, which is why the structure exists.

More Targets?

SPACs widening their sites merging with spun-off divisions provides more opportunities for them to find the ideal and willing merger candidate. Companies looking to sell productive departments may also find that negotiating with potential acquirers that include Special Purpose Acquisition Companies, could benefit all involved.

 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



SPACs, Equity Research, and Bowling



SPAC Supply Provides Rare Opportunity





What Happens if Your SPAC Doesn’t Find its Ideal Acquisition?



Merger of a SPAC, the De-SPAC Phase Explained

 

Sources

https://investor.ligand.com/press-releases/detail/460/ligand-to-spin-off-its-omniab-business-through-merger-with

https://www.businesswire.com/news/home/20220323005896/en/

 

Stay up to date. Follow us:

 

Filament Health Announces Second Patent Issuance



Filament Health Announces Second Patent Issuance

Research, News, and Market Data on Filament Health

 

The patent describes the extraction and standardization of stable doses of psychedelic compounds

VANCOUVER, BCMarch 23, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the Canadian Intellectual Property Office (CIPO) for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.

“The issuance of Filament’s second patent is a testament to the strength of our drug development platform and our grasp of crucial technologies,” said Benjamin Lightburn, Chief Executive Officer. “Valuable medicines can be found in nature and we have built a powerful platform with the ability to transform variable natural substances into a standardized pharmaceutical-grade product.”

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. Previous methods of natural extraction have experienced challenges relating to poor yields, stability, and repeatability.

“Two years ago, conventional wisdom was that producing shelf stable psilocin was impossible,” said Taran Grey, Director of Intellectual Property. “Not only has Filament proved the contrary, we have had our innovations yet again validated by the patent office. According to the Yale Journal of Law and Technology, the success rate for pending applications to issued patents in the pharmaceutical industry is 42.8%. Our success rate is 100%”.

On August 3, 2021, Filament was awarded the first-ever patent for the extraction and standardization of natural psilocybin. This latest successful issuance validates Filament’s intellectual property strategy and sets the Company in good stead for allowances of several pending patent applications covering additional elements of its proprietary technologies and compositions.

ABOUT FILAMENT HEALTH (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.

FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company’s business and the ability of the Company to secure future patents. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE Filament Health Corp.

For further information: MEDIA RELATIONS: Anna Cordon, Director of Communications, 778.245.9067, anna@filament.health; INVESTOR RELATIONS: KCSA Strategic Communications, Tim Regan/Adam Holdsworth, 347.487.6788, KCSA-investor-relations@filament.health

Motorsport Games Partners With Romain Grosjean To Assist In The Development Of rFactor 2 And Esports Events



Motorsport Games Partners With Romain Grosjean To Assist In The Development Of rFactor 2 And Esports Events

Research, News, and Market Data on Motorsport Games

 

JOINING AS A TECHNICAL ADVISOR, GROSJEAN WILL HELP ITERATE RFACTOR 2 AND THE COMPANY’S ROBUST LIVE ESPORTS EVENTS

MIAMI, March 25, 2022 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”), a leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world, announces today that current INDYCAR star and former Formula One driver Romain Grosjean has joined the company as an advisor on its games and esports events, with particular focus on the rFactor 2 simulation platform.

In his role as a technical esports advisor for Motorsport Games, Grosjean will bring all of his racing experience together – both real-life and sim – to help develop the company’s industry-leading rFactor 2 racing simulation. Throughout the year, Grosjean will participate in four technical test sessions for rFactor 2, allowing him to provide feedback and recommendations to implement to further enhance the platform. In addition to his help of iterating rFactor 2, Grosjean will also be available to advise on Motorsport Games’ catalogue of esports events, such as the hugely successful Le Mans Virtual Series and the brand new INDYCAR-Motorsport Games Pro Challenge. His deep knowledge of both will prove key in further expanding each offering, as Grosjean has participated in both real-life competitions during his career.

“The link between real-life racing and sim racing continues to get closer and it has become an increasingly important tool for companies, teams and championships throughout motorsport,” said Romain Grosjean. “I’m very happy to be taking on the role of technical advisor for Motorsport Games and can’t wait to help provide feedback on rFactor 2, a simulation that I frequently use. The company has shown through its esports events such as the Le Mans Virtual Series and the recent INDYCAR-Motorsport Games Pro Challenge that it is perfectly placed to provide top esports through its products and events.”

“While Romain’s experience and skill in real-world motorsport is very well known across the world, he has also shown in recent years that he has an in-depth knowledge and experience of esports and sim racing,” said Gérard Neveu, Motorsport Advisor for Motorsport Games. “Therefore, he is a perfect fit for this new role as technical advisor to Motorsport Games and his vast experience will help us immensely as we develop rFactor 2 and further expand our esports events. As he was recently voted the most popular driver on the entire INDYCAR grid through a Global INDYCAR Fan Survey conducted by Motorsport Games’ parent company, Motorsport Network, in conjunction with Nielsen and INDYCAR, we know our players will be thrilled to see Romain more closely involved with the development of both our simulation platform and events. With Romain, we will be able to take our Le Mans and INDYCAR esports events to the next level.”

To keep up with the latest Motorsport Game news visit www.motorsportgames.com and follow on Twitter, Instagram, Facebook and LinkedIn.

About Motorsport Games:

Motorsport Games, a Motorsport Network company, is a leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world. Combining innovative and engaging video games with exciting esports competitions and content for racing fans and gamers, Motorsport Games strives to make the joy of racing accessible to everyone. The Company is the officially licensed video game developer and publisher for iconic motorsport racing series across PC, PlayStation, Xbox, Nintendo Switch and mobile, including NASCAR, INDYCAR, 24 Hours of Le Mans, rFactor 2, KartKraft and the British Touring Car Championship (“BTCC”). Motorsport Games is an award-winning esports partner of choice for 24 Hours of Le Mans, Formula E, BTCC, the FIA World Rallycross Championship and the eNASCAR Heat Pro League, among others. Motorsport Games is building a virtual racing ecosystem where each product drives excitement, every esports event is an adventure and every story inspires.

Forward-Looking Statements:

Certain statements in this press release which are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are provided pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning: (i) the expected benefits of Motorsport Games’ association with Romain Grosjean including, without limitation, that his vast experience will help Motorsports Games immensely as it develops rFactor 2 and further expand its esports events and that Motorsport Games will be able to take its Le Mans and INDYCAR esports events to the next level. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Motorsport Games and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to the Company experiencing difficulties and/or delays in developing rFactor 2 and expanding its esports events, such as due to higher than anticipated costs incurred in developing, launching and continuing to enhance and improve such products and/or less than anticipated consumer acceptance of the Company’s products and/or difficulties, delays in or unanticipated events that may impact the timing and scope of developing such products, such as due to difficulties or delays in using its product development personnel in Russia due to Russia’s invasion of Ukraine and the related sanctions, delays and higher than anticipated expenses related to the ongoing and prolonged COVID-19 pandemic and related economic lockdowns and government mandates; unanticipated operating costs, transaction costs and actual or contingent liabilities; adverse effects of increased competition; and unanticipated changes in consumer behavior, including as a result of general economic factors, such as increased inflation. Factors other than those referred to above could also cause Motorsport Games’ results to differ materially from expected results. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Motorsport Games and are difficult to predict. Factors other than those referred to above could also cause Motorsport Games’ results to differ materially from expected results. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in Motorsport Games’ filings with the SEC, which may be found at www.sec.gov and at ir.motorsportgames.com, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, its Quarterly Reports on Form 10-Q filed with the SEC during 2021, Current Reports on Form 8-K filed during 2022, as well as in its subsequent filings with the SEC. Motorsport Games anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Motorsport Games assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Motorsport Games’ plans and expectations as of any subsequent date. Additionally, the business and financial materials and any other statement or disclosure on, or made available through, Motorsport Games’ website or other websites referenced or linked to this press release shall not be incorporated by reference into this press release.

Website and Social Media Disclosure:

Investors and others should note that we announce material financial information to our investors using our investor relations website (ir.motorsportgames.com), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media and blogs, to communicate with our investors and the public about our company and our products. It is possible that the information we post on our websites, social media and blogs could be deemed to be material information. Therefore, we encourage investors, the media and others interested in our company to review the information we post on the websites, social media channels and blogs, including the following (which list we will update from time to time on our investor relations website):

Websites Social Media
motorsportgames.com Twitter: @msportgames & @traxiongg
traxion.gg Instagram: msportgames & traxiongg
motorsport.com Facebook: Motorsport Games & traxiongg
  LinkedIn: Motorsport Games
  Twitch: traxiongg
  Reddit: traxiongg

The contents of these websites and social media channels are not part of, nor will they be incorporated by reference into, this press release.

Investors: Ashley DeSimone Ashley.Desimone@icrinc.com

Press: ASTRSK PR motorsportgames@astrskpr.com

Marijuana Hits the House This Spring



Image: Elsa Oloffson (cbdoracle.com)


House Approval Expected for Marijuana Opportunity Reinvestment and Expungement Act (MORE Act)

 

The first week of Spring may be exciting for marijuana businesses, both publicly traded and private. On Thursday (March 24), The House branch of Congress scheduled a vote to legalize cannabis federally, (MORE Act).

As soon as Monday, The U.S. House of Representatives will vote on the Marijuana Opportunity, Reinvestment, and Disposal Act. This bill would remove marijuana from the list of federally controlled substances. The MORE Act is expected to pass, at that point, it would make its way to the Senate for a vote and is expected to eventually wind up on the desk of the President to be signed into law.

Investors viewed this move to put it on the calendar the last week in March as a huge positive which then pushed cannabis-related stocks higher. Medicine Man Technologies – Schwazze (SHWZ) saw its shares leap 10.48% on Thursday.  SHWZ is involved in production, consulting, and retailing. Stem Holdings (STMH), is involved in properties used in cannabis agriculture, it saw its shares jump 9.37%. Both SHWZ and STMH are small, growth companies with equity research coverage provided on Channelchek, by Noble Capital Markets. Other cannabis companies involved in various ends of the business, both large and small saw similar movement.

The federal legalization of marijuana has bipartisan support in Congress. While it is widely expected to pass in the House and Senate, it is not certain whether President Biden will sign. Senate Majority Leader Schumer has been lobbying President Biden on the positive implications of legal marijuana and has expressed hope Biden will support the law.

Cannabis is legal for recreational use in 18 states and for medical use in 38. Federal recreational drug legalization would dramatically increase the market for cannabis growers, refiners, and distributors while eliminating concerns over banking and securities laws related to involvement in federally illegal businesses.

 

 

Sources

https://www.congress.gov/bill/117th-congress/house-bill/3617/

https://norml.org/blog/2022/03/24/us-house-of-representatives-to-vote-on-more-act-next-week/

 

Stay up to date. Follow us:

 

One Stop Systems (OSS) – 4Q21: Revenue Beat, Miss On Earnings, But Bright Future

Friday, March 25, 2022

One Stop Systems (OSS)
4Q21: Revenue Beat, Miss On Earnings, But Bright Future

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems. The product line of the company includes GPU Appliances, GPU Expansion, GPUs and co-processors, Flash storage arrays, Flash storage expansion, Servers, Disk Arrays, Desktop computing appliances, accessories and parts. The company delivers high-end technology to customers through the sale of equipment and software for use on their premises or through remote cloud access to secure data centres housing technology.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q21 Results. Fourth quarter revenue of $17.8 million, up 28% y-o-y and up 11% sequentially, and above management’s $17.1 million guide. We had forecast $17.1 million. GAAP net loss of $386,000, or $0.02 per share, versus net income of $244,000, or $0.01 per share, last year. Adjusted net income of $71,000, or breakeven, versus $636,000, or $0.04 per share in 4Q20. We had forecast $0.04 and $0.07 respectively.

    Too Much Business? During 4Q21 Disguise revenue rose 247% y-o-y and resulted in gross margin declining to 28.3% in the quarter from 34.5% in the same period last year.  Increased operating expenses, driven by Market and Selling costs, with the lower gross margin caused an operating loss for the quarter. We anticipate Disguise business to return to a normal percentage of overall revenue going forward …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Townsquare Media (TSQ) – A Cherry Of A Deal

Friday, March 25, 2022

Townsquare Media (TSQ)
A Cherry Of A Deal

Townsquare Media Inc is an entertainment and media company offering digital marketing solutions in the United States and Canada. It owns and operates radio stations, social media properties focusing the small and mid-cap companies. Services offered to the clients include live events, local advertising, digital advertising, e-commerce offerings, few others. The segments through which the company operates its businesses are classified into Local marketing solutions and Entertainment segments. Revenues are generated from commercials through broadcasts and sale of internet based advertisements.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Expands its radio footprint. The company plans to acquire Cherry Creek Broadcasting’s 35 stations in nine markets for $18.75 million. Given overlap in certain markets, the company plans to divest six radio stations. The transaction is expected to close in Q3 2022. The company will now serve a platform of 356 local stations in 74 markets, up from 67. We estimate that the company paid an attractive multiple, less than 7 times cash flow.

    Plans to introduce Digital solutions.  Management indicated that the stations offer the ability to employ its Digital First strategy, with Townsquare Ignite, its programmatic advertising business, and Townsquare Interactive, its subscription based, digital agency business. As such, we anticipate enhanced Digital revenue and adj. EBITDA growth from the acquired stations …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Release – Comstock Announces 2022 Annual Meeting



Comstock Announces 2022 Annual Meeting

Research, News, and Market Data on Comstock Mining

 

VIRGINIA CITY, Nev., March 24, 2022 (GLOBE NEWSWIRE) — Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced that its 2022 Annual Meeting of Shareholders has been scheduled for Thursday, May 26, 2022, starting at 9:00 a.m. Pacific Daylight Time in Reno, Nevada, at the Atlantis Hotel. The meeting will feature Comstock’s renewable fuels and electrification businesses, and highlight the Company’s expanded senior management team and recently expanded portfolio of decarbonizing technologies.

The 2022 Annual Meeting schedule for May 26, 2022, is as follows:

   
8:00 am to 9:00 am PDT Continental Breakfast
9:00 am to 11:30 am PDT 2022 Annual Shareholders Meeting, Company Presentations, Q & A
12:00 pm to 2:00 pm PDT Lunch and Conversations with Company Management and Directors
   

The record date for the Annual Meeting is March 31, 2022. Only shareholders of record at the close of business on March 31, 2022, may vote at the meeting. The Company’s proxy statement will be sent to shareholders of record and will describe all matters to be voted on, including the Company’s name change to Comstock Inc. Shareholders are invited to register for the 2022 Annual Meeting at Comstock’s newly released website at www.comstock.inc.

About Comstock Mining Inc.
Comstock Mining Inc. (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting massive supplies of under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Forward-Looking Statements
This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in reports that we file with the Securities and Exchange Commission, including Item 1A, “Risk Factors” in our most recently-filed Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, mercury remediation and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mercury remediation, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with mercury remediation, metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, mercury remediation technology and efficacy, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Contact information:

   
Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
ComstockMining.com
Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com
Zach Spencer
Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com

Release – Neovasc Announces Consolidation and Extension of Convertible Debt



Neovasc Announces Consolidation and Extension of Convertible Debt

Research, News, and Market Data on Neovasc

 

VANCOUVER – ( NewMediaWire ) – March 24, 2022 – Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) (“Neovasc” or the “Company”), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that, pursuant to a Restated Securities Purchase Agreement with Strul Medical Group LLC (“SMG”), on a private placement basis (the “Private Placement”), it has issued an amended and restated convertible note (the “2022 Restated Note”).

The 2022 Restated Note was issued in an aggregate principal amount of $13,000,000 and consolidates the amount owed by the Company under certain convertible notes the Company issued to SMG in 2019 and 2020. The Company paid out in cash an additional amount of $290,961 that was owed under the 2019 and 2020 notes.

The 2022 Restated Note matures on December 31, 2025 (the “Maturity Date”) and bears interest at a rate of 9% per annum, compounded quarterly, a portion of which is payable in cash at the end of June and December annually and the rest due on the Maturity Date. The 2022 Restated Note is convertible into common shares of the Company (the “Common Shares”) at a price of $1.00 per Common Share for up to 15,674,184 Common Shares comprised of the principal amount and accrued and unpaid interest. The 2022 Restated Note is subject to a four month and one day hold period.

The transaction was conducted in accordance with Section 602.1 of the TSX Company Manual, which provides that the Toronto Stock Exchange will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Capital Market (the “Nasdaq”).

“We are very pleased to continue with our support of Neovasc as they advance their development strategies for both Reducer and Tiara,” said Aubrey Strul, a Principal of SMG. “We continue to have confidence in Fred and the Neovasc team to achieve critical milestones during the term of the Note.”

“This is an important development for our cash requirements in the coming years. It combines and extends the terms of our current notes with the SMG beyond our targeted date for the readout of our COSIRA II clinical study and an anticipated decision from the FDA on our application for approval to commercialize the Reducer in the United States,” stated Fred Colen, President and Chief Executive Officer of Neovasc. “We have reviewed opportunities, that might generally be available to us in the debt market, and given our company status and market conditions, we came to the conclusion that this debt restructuring agreement with the SMG is the best option available to Neovasc.”

This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. The securities have not been and will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and TiaraTMfor the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com .

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to SMG’s belief in the Company’s management to achieve critical milestones, the importance of the Private Placement on the Company’s cash requirements in the future, the targeted date timeline for the COSIRA-II study, the anticipated timeline of the FDA decision and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks around the Company’s ability to continue as a going concern; risks around the Company’s history of losses and significant accumulated deficit; risks related to the recent COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company’s operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company’s expected schedule; risks relating to the Company’s need for significant additional future capital and the Company’s ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company’s Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s conclusion that it did have effective internal control over financial reporting as of December 31, 2021 and 2020 but not at December 31, 2019; risks relating to the Common Share price being volatile; risks relating to the Company’s significant indebtedness, and its effect on the Company’s financial condition; risks relating to the influence of significant shareholders of the Company over our business operations and share price; risks relating to lawsuits that the Company is subject to, which could divert the Company’s resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company’s ability to establish, maintain and defend intellectual property rights in the Company’s products; risks relating to results from clinical trials of the Company’s products, which may be unfavorable or perceived as unfavorable; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company’s products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company’s ability to achieve or maintain expected levels of market acceptance for the Company’s products, as well as the Company’s ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company’s ability to convince public payors and hospitals to include the Company’s products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company’s products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company’s products; risks relating to health and safety concerns associated with the Company’s products and industry; risks relating to the Company’s manufacturing operations, including the regulation of the Company’s manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company’s products; risks relating to the manufacturing capacity of third-party manufacturers for the Company’s products, including risks of supply interruptions impacting the Company’s ability to manufacture its own products; risks relating to the Company’s dependence on limited products for substantially all of the Company’s current revenues; risks relating to the Company’s exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a “passive foreign investment company”; risks relating to breaches of anti-bribery laws by the Company’s employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company’s dependence upon key personnel to achieve its business objectives; risks relating to the Company’s ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company’s management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company’s ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company’s officers and directors as a result of their involvement with other issuers; risks relating to future issuances of equity securities by the Company, or sales of common shares or conversions of convertible notes, and exercise of warrants, options and restricted stock units by our existing security holders, causing the price of the Company’s securities to fall; and risks relating to anti-takeover provisions in the Company’s constating documents which could discourage a third-party from making a takeover bid beneficial to the Company’s shareholders. These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Report on Form 20-F and 40-F for the years ended December 31, 2021 and 2020 (copies of which may be obtained at www.sec.gov ). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov ), whether because of new information, future events or otherwise, except as required by law.

Investors:
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com 

Media:
Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com 

Release – ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit



ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

News and Market Data on ProMIS Neurosciences

 

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.

ProMIS Chief Scientific Officer, Dr. Neil Cashman, will deliver an oral presentation entitled: “Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distractionon Tuesday, March 29, 2022, at 3 PM local time at the Boston Park Plaza Hotel.

Much scientific data has implicated misfolded oligomers as the toxic molecular species of amyloid beta (Abeta) relevant to Alzheimer’s disease. However, using conventional methods, it has proven difficult to selectively target oligomers while sparing other species – including monomers and fibrils – which “distract” a therapeutic antibody from its primary target. Immune recognition of Abeta fibrils can also lead to dose-limiting adverse effects. In his presentation, Dr. Cashman will discuss the use of Collective CoordinatesTM, a proprietary computational algorithm, to design conformational epitopes that specifically target oligomers, while sparing monomers and fibrils from immune recognition.

Dr. Cashman’s presentation will be available on the ProMIS website (www.promisneurosciences.com) at the conclusion of the meeting. For more information about the meeting please consult the organizer’s website here.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF

To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: ProMIS Neurosciences Inc.

What is the Yield Curve




Why Investors Monitor the Yield Curve and Yield Curve Changes

 

The difference between interest rates being paid for all available maturities of the same credit quality bonds and notes forms the yield curve. When these points are plotted on a line graph, the shape of the line is the “curve.” The US Treasury Yield curve is by far the most discussed. However, there are yield curves for corporate bonds, mortgage securities, municipal bonds, and other interest rate products. But these are often quoted as an interest rate spread to the US Treasury yield curve.

 

Data: US
Department of Treasury

 

The shape of a yield curve—where the Y-axis is interest rates, and the X-axis shows increasing time to maturity— can take on different shapes. The most common are upward sloping or “normal yield curve,”
downward sloping,
or “inverted yield curve,” and flat.

The significance of these shapes has historically been used by
stock
market
investors as a gauge of future expectations of economic activity and inflation. A normal yield curve indicates expectations of a growing economy, and the risk of rates being pushed up over time. A downward-sloping yield curve indicates expectations of a contracting economy or one where interest rates may need to be lowered in the future. A flat yield curve typically indicates expectations of a stagnant economy. This is also viewed as negative for stocks because equity investors like to see economic growth.

Shifts in Curve

Changes in rates from one period to the next will cause changes in the shape or steepness of the curve. The graph above shows the shift in yields from March 1, 2022 to March 23, 2022 – the Fed
tightened
overnight rates by 25 bp on March 16, then on March 21, indicated a need to further increase rates. This caused a steepening.

Shifts in the curve indicate whether bond investor sentiment for higher rates is increasing or decreasing. Historically this has been based on an accelerating or decelerating economy and a changed inflation forecast. Bond market investors want to be compensated for inflation. In recent years the US Federal Reserve has taken steps that include buying bonds to adjust longer rates or add liquidity to the market. This impacts the usefulness of the curve, so investors ought to take these actions into account. There is now increased importance of Fed
announcements
surrounding these purchase activities (sometimes referred to as yield-curve-control, quantitative easing, or QE). A reduction in Fed purchases (
tapering) will tend to push longer-term rates up as the Fed has been a significant buyer of the maturity range they targeted with QE. 

 

You May Also Be Interested In:



What is Fed Tightening



Merger of a SPAC

 

 

Stay up to date. Follow us:

 

Unraveling Stem Cells Secrets



Image of Yukiko Yamashita, courtesy of MIT


Research has Shed Light on the Immortality of Germline Cells and the Function of “Junk DNA”

 

Anne Trafton | MIT News
Office

 

When cells divide, they usually generate two identical daughter cells. However, there are some important exceptions to this rule: When stem cells divide, they often produce one differentiated cell along with another stem cell, to maintain the pool of stem cells.

Yukiko Yamashita has spent much of her career exploring how these “asymmetrical” cell divisions occur. These processes are critically important not only for cells to develop into different types of tissue, but also for germline cells such as eggs and sperm to maintain their viability from generation to generation.

“We came from our parents’ germ cells, who used to be also single cells who came from the germ cells of their parents, who used to be single cells that came from their parents, and so on. That means our existence can be tracked through the history of multicellular life,” Yamashita says. “How germ cells manage to not go extinct, while our somatic cells cannot last that long, is a fascinating question.”

Yamashita, who began her faculty career at the University of Michigan, joined MIT and the Whitehead Institute in 2020, as the inaugural holder of the Susan Lindquist Chair for Women in Science and a professor in the Department of Biology. She was drawn to MIT, she says, by the eagerness to explore new ideas that she found among other scientists.

“When I visited MIT, I really enjoyed talking to people here,” she says. “They are very curious, and they are very open to unconventional ideas. I realized I would have a lot of fun if I came here.”

 

Exploring Paradoxes

Before she even knew what a scientist was, Yamashita knew that she wanted to be one.

“My father was an admirer of Albert Einstein, so because of that, I grew up thinking that the pursuit of the truth is the best thing you could do with your life,” she recalls. “At the age of 2 or 3, I didn’t know there was such a thing as a professor, or such a thing as a scientist, but I thought doing science was probably the coolest thing I could do.”

Yamashita majored in biology at Kyoto University and then stayed to pursue her PhD, studying how cells make exact copies of themselves when they divide. As a postdoc at Stanford University, she became interested in the exceptions to that carefully orchestrated process, and began to study how cells undergo divisions that produce daughter cells that are not identical. This kind of asymmetric division is critical for multicellular organisms, which begin life as a single cell that eventually differentiates into many types of tissue.

Those studies led to a discovery that helped to overturn previous theories about the role of so-called junk DNA. These sequences, which make up most of the genome, were thought to be essentially useless because they don’t code for any proteins. To Yamashita, it seemed paradoxical that cells would carry so much DNA that wasn’t serving any purpose.

“I couldn’t really believe that huge amount of our DNA is junk, because every time a cell divides, it still has the burden of replicating that junk,” she says. “So, my lab started studying the function of that junk, and then we realized it is a really important part of the chromosome.”

In human cells, the genome is stored on 23 pairs of chromosomes. Keeping all of those chromosomes together is critical to cells’ ability to copy genes when they are needed. Over several years, Yamashita and her colleagues at the University of Michigan, and then at MIT, discovered that stretches of junk DNA act like bar codes, labeling each chromosome and helping them bind to proteins that bundle chromosomes together within the cell nucleus.

Without those barcodes, chromosomes scatter and start to leak out of the cell’s nucleus. Another intriguing observation regarding these stretches of junk DNA was that they have much greater variability between different species than protein-coding regions of DNA. By crossing two different species of fruit flies, Yamashita showed that in cells of the hybrid offspring flies, chromosomes leak out just as they would if they lost their barcodes, suggesting that the codes are specific to each species.

“We think that might be one of the big reasons why different species become incompatible, because they don’t have the right information to bundle all of their chromosomes together into one place,” Yamashita says.

 

Stem Cell Longevity

Yamashita’s interest in stem cells also led her to study how germline cells (the cells that give rise to eggs and sperm cells) maintain their viability so much longer than regular body cells across generations. In typical animal cells, one factor that contributes to age-related decline is loss of genetic sequences that encode genes that cells use continuously, such as genes for ribosomal RNAs.

A typical human cell may have hundreds of copies of these critical genes, but as cells age, they lose some of them. For germline cells, this can be detrimental because if the numbers get too low, the cells can no longer form viable daughter cells.

Yamashita and her colleagues found that germline cells overcome this by tearing sections of DNA out of one daughter cell during cell division and transferring them to the other daughter cell. That way, one daughter cell has the full complement of those genes restored, while the other cell is sacrificed.

That wasteful strategy would likely be too extravagant to work for all cells in the body, but for the small population of germline cells, the tradeoff is worthwhile, Yamashita says.

“If skin cells did that kind of thing, where every time you make one cell, you are essentially trashing the other one, you couldn’t afford it. You would be wasting too many resources,” she says. “Germ cells are not critical for viability of an organism. You have the luxury to put many resources into them but then let only half of the cells recover.”

 

Suggested Content



What Cells Can be Made from Stem Cells?



Scientists Now Better Understand Viral Mutations





Stem Cells Role in the Anti-Aging Business



Ultra-Rapid DNA Sequencing Identifies Rare Diseases in Hours

 

Stay up to date. Follow us:

 

Unraveling Stem Cell’s Secrets



Image of Yukiko Yamashita, courtesy of MIT


Research has Shed Light on the Immortality of Germline Cells and the Function of “Junk DNA”

 

Anne Trafton | MIT News
Office

 

When cells divide, they usually generate two identical daughter cells. However, there are some important exceptions to this rule: When stem cells divide, they often produce one differentiated cell along with another stem cell, to maintain the pool of stem cells.

Yukiko Yamashita has spent much of her career exploring how these “asymmetrical” cell divisions occur. These processes are critically important not only for cells to develop into different types of tissue, but also for germline cells such as eggs and sperm to maintain their viability from generation to generation.

“We came from our parents’ germ cells, who used to be also single cells who came from the germ cells of their parents, who used to be single cells that came from their parents, and so on. That means our existence can be tracked through the history of multicellular life,” Yamashita says. “How germ cells manage to not go extinct, while our somatic cells cannot last that long, is a fascinating question.”

Yamashita, who began her faculty career at the University of Michigan, joined MIT and the Whitehead Institute in 2020, as the inaugural holder of the Susan Lindquist Chair for Women in Science and a professor in the Department of Biology. She was drawn to MIT, she says, by the eagerness to explore new ideas that she found among other scientists.

“When I visited MIT, I really enjoyed talking to people here,” she says. “They are very curious, and they are very open to unconventional ideas. I realized I would have a lot of fun if I came here.”

 

Exploring Paradoxes

Before she even knew what a scientist was, Yamashita knew that she wanted to be one.

“My father was an admirer of Albert Einstein, so because of that, I grew up thinking that the pursuit of the truth is the best thing you could do with your life,” she recalls. “At the age of 2 or 3, I didn’t know there was such a thing as a professor, or such a thing as a scientist, but I thought doing science was probably the coolest thing I could do.”

Yamashita majored in biology at Kyoto University and then stayed to pursue her PhD, studying how cells make exact copies of themselves when they divide. As a postdoc at Stanford University, she became interested in the exceptions to that carefully orchestrated process, and began to study how cells undergo divisions that produce daughter cells that are not identical. This kind of asymmetric division is critical for multicellular organisms, which begin life as a single cell that eventually differentiates into many types of tissue.

Those studies led to a discovery that helped to overturn previous theories about the role of so-called junk DNA. These sequences, which make up most of the genome, were thought to be essentially useless because they don’t code for any proteins. To Yamashita, it seemed paradoxical that cells would carry so much DNA that wasn’t serving any purpose.

“I couldn’t really believe that huge amount of our DNA is junk, because every time a cell divides, it still has the burden of replicating that junk,” she says. “So, my lab started studying the function of that junk, and then we realized it is a really important part of the chromosome.”

In human cells, the genome is stored on 23 pairs of chromosomes. Keeping all of those chromosomes together is critical to cells’ ability to copy genes when they are needed. Over several years, Yamashita and her colleagues at the University of Michigan, and then at MIT, discovered that stretches of junk DNA act like bar codes, labeling each chromosome and helping them bind to proteins that bundle chromosomes together within the cell nucleus.

Without those barcodes, chromosomes scatter and start to leak out of the cell’s nucleus. Another intriguing observation regarding these stretches of junk DNA was that they have much greater variability between different species than protein-coding regions of DNA. By crossing two different species of fruit flies, Yamashita showed that in cells of the hybrid offspring flies, chromosomes leak out just as they would if they lost their barcodes, suggesting that the codes are specific to each species.

“We think that might be one of the big reasons why different species become incompatible, because they don’t have the right information to bundle all of their chromosomes together into one place,” Yamashita says.

 

Stem Cell Longevity

Yamashita’s interest in stem cells also led her to study how germline cells (the cells that give rise to eggs and sperm cells) maintain their viability so much longer than regular body cells across generations. In typical animal cells, one factor that contributes to age-related decline is loss of genetic sequences that encode genes that cells use continuously, such as genes for ribosomal RNAs.

A typical human cell may have hundreds of copies of these critical genes, but as cells age, they lose some of them. For germline cells, this can be detrimental because if the numbers get too low, the cells can no longer form viable daughter cells.

Yamashita and her colleagues found that germline cells overcome this by tearing sections of DNA out of one daughter cell during cell division and transferring them to the other daughter cell. That way, one daughter cell has the full complement of those genes restored, while the other cell is sacrificed.

That wasteful strategy would likely be too extravagant to work for all cells in the body, but for the small population of germline cells, the tradeoff is worthwhile, Yamashita says.

“If skin cells did that kind of thing, where every time you make one cell, you are essentially trashing the other one, you couldn’t afford it. You would be wasting too many resources,” she says. “Germ cells are not critical for viability of an organism. You have the luxury to put many resources into them but then let only half of the cells recover.”

 

Suggested Content



What Cells Can be Made from Stem Cells?



Scientists Now Better Understand Viral Mutations





Stem Cells Role in the Anti-Aging Business



Ultra-Rapid DNA Sequencing Identifies Rare Diseases in Hours

 

Stay up to date. Follow us: